FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950528384> ?p ?o ?g. }

• W2950528384 endingPage "5029" @default.
• W2950528384 startingPage "5017" @default.
• W2950528384 abstract "A novel series of (2R)-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamides was designed and synthesized based on the structure and biological profiles of an active metabolite 2 of our prototype muscarinic M(3) receptor selective antagonist 1, to develop a potent, long-acting, orally active M(3) antagonist for the treatment of urinary tract disorders, irritable bowel syndrome, and respiratory disorders. Investigation of (2R)-2-[(1R)-3, 3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamides containing a phenyl or heterocyclic ring as the piperidinyl side chain in place of the 4-methyl-3-pentenyl moiety of 15a revealed that this acid moiety was a versatile template for improving the selectivity for M(3) over M(2) receptors in comparison with the corresponding cyclopentylphenylacetic acid group. However, since the in vitro metabolic stability of these analogues was insufficient compared with that of 2, further derivatization was performed by introducing an appropriate hydrophilic group into the phenyl or 2-pyridyl ring. Thus, the 1-(6-aminopyridin-2-ylmethyl)piperidine analogue 15y exhibiting 190-fold selectivity for M(3) receptors (K(i) = 2.8 nM) over M(2) receptors (K(i) = 530 nM) in a human binding assay and good in vitro metabolic stability in dog and human hepatic microsomes was identified. This compound has excellent oral activity at 4 h after oral dosing (1 mg/kg), inhibiting methacholine-induced bronchoconstriction in dogs, and may be useful in clinical situations in which M(3) over M(2) selectivity is desirable." @default.
• W2950528384 created "2019-06-27" @default.
• W2950528384 creator A5009721022 @default.
• W2950528384 creator A5010785607 @default.
• W2950528384 creator A5012680834 @default.
• W2950528384 creator A5017141269 @default.
• W2950528384 creator A5032388871 @default.
• W2950528384 creator A5032447442 @default.
• W2950528384 creator A5047495331 @default.
• W2950528384 creator A5051962919 @default.
• W2950528384 creator A5058796976 @default.
• W2950528384 creator A5061391588 @default.
• W2950528384 creator A5065576234 @default.
• W2950528384 creator A5066920469 @default.
• W2950528384 creator A5078572797 @default.
• W2950528384 creator A5084410740 @default.
• W2950528384 date "2000-11-28" @default.
• W2950528384 modified "2023-09-27" @default.
• W2950528384 title "A Potent, Long-Acting, Orally Active (2<i>R</i>)-2-[(1<i>R</i>)-3,3-Difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: A Novel Muscarinic M₃ Receptor Antagonist with High Selectivity for M₃ over M₂ Receptors" @default.
• W2950528384 cites W1638610891 @default.
• W2950528384 cites W1769215519 @default.
• W2950528384 cites W1972351611 @default.
• W2950528384 cites W1972961295 @default.
• W2950528384 cites W1974018894 @default.
• W2950528384 cites W1978745809 @default.
• W2950528384 cites W1982269721 @default.
• W2950528384 cites W1995806931 @default.
• W2950528384 cites W2000902055 @default.
• W2950528384 cites W2044940362 @default.
• W2950528384 cites W2052838036 @default.
• W2950528384 cites W2060110594 @default.
• W2950528384 cites W2069298474 @default.
• W2950528384 cites W2075035957 @default.
• W2950528384 cites W2113630547 @default.
• W2950528384 cites W2161685942 @default.
• W2950528384 cites W3100365739 @default.
• W2950528384 doi "https://doi.org/10.1021/jm0003135" @default.
• W2950528384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11150173" @default.
• W2950528384 hasPublicationYear "2000" @default.
• W2950528384 type Work @default.
• W2950528384 sameAs 2950528384 @default.
• W2950528384 citedByCount "42" @default.
• W2950528384 countsByYear W29505283842012 @default.
• W2950528384 countsByYear W29505283842013 @default.
• W2950528384 countsByYear W29505283842014 @default.
• W2950528384 countsByYear W29505283842015 @default.
• W2950528384 countsByYear W29505283842018 @default.
• W2950528384 countsByYear W29505283842020 @default.
• W2950528384 countsByYear W29505283842021 @default.
• W2950528384 countsByYear W29505283842022 @default.
• W2950528384 crossrefType "journal-article" @default.
• W2950528384 hasAuthorship W2950528384A5009721022 @default.
• W2950528384 hasAuthorship W2950528384A5010785607 @default.
• W2950528384 hasAuthorship W2950528384A5012680834 @default.
• W2950528384 hasAuthorship W2950528384A5017141269 @default.
• W2950528384 hasAuthorship W2950528384A5032388871 @default.
• W2950528384 hasAuthorship W2950528384A5032447442 @default.
• W2950528384 hasAuthorship W2950528384A5047495331 @default.
• W2950528384 hasAuthorship W2950528384A5051962919 @default.
• W2950528384 hasAuthorship W2950528384A5058796976 @default.
• W2950528384 hasAuthorship W2950528384A5061391588 @default.
• W2950528384 hasAuthorship W2950528384A5065576234 @default.
• W2950528384 hasAuthorship W2950528384A5066920469 @default.
• W2950528384 hasAuthorship W2950528384A5078572797 @default.
• W2950528384 hasAuthorship W2950528384A5084410740 @default.
• W2950528384 hasConcept C114373084 @default.
• W2950528384 hasConcept C118792377 @default.
• W2950528384 hasConcept C149151106 @default.
• W2950528384 hasConcept C161790260 @default.
• W2950528384 hasConcept C170493617 @default.
• W2950528384 hasConcept C185592680 @default.
• W2950528384 hasConcept C202751555 @default.
• W2950528384 hasConcept C24961977 @default.
• W2950528384 hasConcept C2776568683 @default.
• W2950528384 hasConcept C2776885963 @default.
• W2950528384 hasConcept C2777477808 @default.
• W2950528384 hasConcept C33789571 @default.
• W2950528384 hasConcept C55493867 @default.
• W2950528384 hasConcept C71240020 @default.
• W2950528384 hasConcept C71924100 @default.
• W2950528384 hasConcept C98274493 @default.
• W2950528384 hasConceptScore W2950528384C114373084 @default.
• W2950528384 hasConceptScore W2950528384C118792377 @default.
• W2950528384 hasConceptScore W2950528384C149151106 @default.
• W2950528384 hasConceptScore W2950528384C161790260 @default.
• W2950528384 hasConceptScore W2950528384C170493617 @default.
• W2950528384 hasConceptScore W2950528384C185592680 @default.
• W2950528384 hasConceptScore W2950528384C202751555 @default.
• W2950528384 hasConceptScore W2950528384C24961977 @default.
• W2950528384 hasConceptScore W2950528384C2776568683 @default.
• W2950528384 hasConceptScore W2950528384C2776885963 @default.
• W2950528384 hasConceptScore W2950528384C2777477808 @default.
• W2950528384 hasConceptScore W2950528384C33789571 @default.
• W2950528384 hasConceptScore W2950528384C55493867 @default.
• W2950528384 hasConceptScore W2950528384C71240020 @default.
• W2950528384 hasConceptScore W2950528384C71924100 @default.
• W2950528384 hasConceptScore W2950528384C98274493 @default.
• W2950528384 hasIssue "26" @default.

• next